GlassScriptPhysician profile
Jakeb Daniel Riggle
NPI 1710336342
$13,153.80
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2021: $353 · 2022: $333 · 2023: $639 · 2024: $820 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,099 · Food and Beverage: $2,371 · Consulting Fee: $1,581 · Travel and Lodging: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,099.00 |
| Food and Beverage | $2,370.50 |
| Consulting Fee | $1,581.00 |
| Travel and Lodging | $1,302.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,365.86 | 2025 | |
| Genzyme Corporation | $1,712.14 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $921.28 | 2022-2025 | Fasenra, Breztri, Airsupra |
| La Jolla Pharmaceutical Company | $260.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.13 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $229.59 | 2022-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $202.84 | 2021-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $170.91 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Harmony Biosciences LLC | $161.33 | 2022-2025 | Wakix |
| Glaxosmithkline, LLC. | $158.12 | 2021-2025 | Nucala |
| United Therapeutics Corporation | $144.66 | 2023-2025 | Remodulin, Orenitram |
| Amgen INC. | $132.06 | 2022-2025 | Tezspire, Tavneos |
| Jazz Pharmaceuticals INC. | $63.36 | 2022-2024 | Xywav |
| Resmed Corp | $48.15 | 2025 | |
| Insmed, INC. | $47.86 | 2024-2025 | Arikayce, Brinsupri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $43.72 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $39.21 | 2025 | Ohtuvayre |
| Electromed, INC. | $38.03 | 2022-2025 | Smartvest |
| Axsome Therapeutics, INC. | $27.47 | 2022-2024 | Sunosi |
| Azurity Pharmaceuticals, INC. | $18.33 | 2024 | Horizant |
| Philips North America LLC | $16.11 | 2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $15.95 | 2023 | |
| Mallinckrodt Hospital Products INC. | $15.05 | 2024 | Acthar |
| Lilly USA, LLC | $14.98 | 2025 | Zepbound |
| Pfizer INC. | $14.97 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $14.15 | 2023 | Lumryz |
| Viatris Specialty LLC | $13.57 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jakeb Riggle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.